Navigation Links
CardioMEMS, Inc. wins 2012 Intel Innovation Award
Date:12/11/2012

ATLANTA, Dec. 11, 2012 /PRNewswire/ -- CardioMEMS, Inc., an Atlanta-based medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, announced today that it has been honored as the 2012 recipient of the Intel Innovation Award.  Founder and CEO Jay Yadav, M.D., was presented with the award on December 4th during the annual Health IT Leadership Summit held at the historic Fox Theatre in Atlanta, GA. 

"CardioMEMS unites two areas where Georgia has strengths – health IT and medical devices," said David B. Hartnett, Vice President, Bioscience & Health IT Development, Metro Atlanta Chamber. "This truly innovative company integrates these two disciplines to create advanced technology that holds huge promise for heart failure patients. We are proud that they are part of the Atlanta healthcare community, and look forward to watching their continued success."

"It was a challenging decision, given the high level of competition for this award," said Dan Rivera, Area Director, Intel Americas.  "Ultimately, CardioMEMS was chosen as the winner based on its ground-breaking technology and novel use of health IT to reduce the burden on our healthcare system."

"We are honored to be recognized by Intel, a leader in innovative solutions," said Dr. Yadav. "This is a testament to the extraordinary efforts of the CardioMEMS team to generate precise, timely, actionable information to address the tremendous burden heart failure places on the U.S. healthcare system and on patients suffering from this debilitating disease.  We are fortunate to have the considerable support of the Technology Association of Georgia, the Metro Atlanta Chamber and the Georgia Department of Economic Development as we continue to bring CardioMEMS' revolutionary technology to market."

About CardioMEMS, Inc.
CardioMEMS is a medical device company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body. The Company's technology platform is designed to improve the management of severe chronic cardiovascular diseases such as aneurysms, heart failure and hypertension. CardioMEMs miniature wireless sensors can be implanted using minimally-invasive techniques and transmit cardiac output, blood pressure and heart rate data which are critical to the management of patients. The sensors are designed to be permanently implanted into the heart and blood vessels due to their small size, durability and lack of wires and batteries. Using radiofrequency energy, the sensors transmit real-time data to external electronic readers, which then communicate this information to the patient's physician. The Company developed this technology based on the belief that frequent, on-demand, real-time monitoring of vital information enables proactive patient management, which holds the promise of reducing hospitalizations, improving a patient's quality of life and delivering more efficient and cost effective health care. More information about the CardioMEMs is located at www.cardiomems.com.

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

CardioMEMS, Champion and the CardioMEMS logo are registered trademarks of CardioMEMS, Inc.

Caution: The Champion Heart Failure Monitoring System is an investigational device limited by federal law to investigational use.


'/>"/>
SOURCE CardioMEMS, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
2. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
3. Intelsius Launches Highest Performing Products
4. IntelligentMDx Announces CE-Marking of a new high-throughput test for Group B Streptococcus intended to improve womens health and prenatal care
5. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
6. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
7. iBio Announces Important Expansion of its Intellectual Property Portfolio: Allowance of Patent for Anthrax Vaccines and Further Application of Modulator Platform
8. Thomson Reuters Speeds Regulatory Decision Making with New Pharmaceutical Intelligence Solution
9. Sterne, Kessler, Goldstein & Fox Selected by 15 Year Old Winner of Intel International Science and Engineering Fair
10. Supplier Marketing Spend Activity, Marketing and Sales Behaviors and Strategies in the Medical Devices Industry - 2012-2013 : Survey Intelligence
11. Buyer Spend Activity and Procurement Behaviors and Strategies in the Pharmaceutical Industry - 2012-2013 : Survey Intelligence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2017)... Sept. 13, 2017   OrthoAtlanta has been named ... Football Host Committee (AFHC) for the 2018 College Football Playoff ... 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... AFHC "I,m In" campaign, participating in many activities leading up ... ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE ... Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, California, who will ... Administration at St. Thomas University in Miami, Florida, was selected from a pool ...
(Date:9/22/2017)... HOUSTON, Texas (PRWEB) , ... September 22, 2017 ... ... leading network of independent freestanding emergency rooms is celebrating the one year anniversary ... anniversary of our facility opening,” said Dr. Otinwa, Facility Medical Director of First ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... products at customers’ doorstep. According to Smart Mart, customers can now order vegetable, ... offer wearable, and customers can find clothing at discounted prices. Apart from this, ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality ... run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves staring ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... in their communities, nine governmental public health departments have been awarded five-year accreditation ... decisions mean that the benefits of being served by a PHAB-accredited health ...
Breaking Medicine News(10 mins):